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Summary
A new computational docking protocol has been de-
veloped and used in combination with conformational
information inferred from REDOR-NMR experiments on
microtubule bound 2-(p-fluorobenzoyl)paclitaxel to de-
lineate a unique tubulin binding structure of paclitaxel.
A conformationally constrained macrocyclic taxoid bear-
ing a linker between the C-14 and C-3N positions has
been designed and synthesized to enforce this “RE-
DOR-taxol” conformation. The novel taxoid SB-T-2053
inhibits the growth of MCF-7 and LCC-6 human breast
cancer cells (wild-type and drug resistant) on the
same order of magnitude as paclitaxel. Moreover, SB-
T-2053 induces in vitro tubulin polymerization at least
as well as paclitaxel, which directly validates our drug
design process. These results open a new avenue for
drug design of next generation taxoids and other
microtubule-stabilizing agents based on the refined
structural information of drug-tubulin complexes, in
accordance with typical enzyme-inhibitor medicinal
chemistry precepts.
Introduction
Taxol (paclitaxel) [1] and Taxotere (docetaxel) [2] (Figure
1) currently serve as two leading chemotherapeutic drugs
in the clinic [3–5]. Both drugs bind to the β-tubulin sub-
unit of the α,β-tubulin heterodimer and act through an
antimitotic mechanism of action based on stabilization
of microtubules (MTBs), thus disrupting the mitosis of
cancer cells and eventually leading to apoptosis [6–9].
Over the last two decades, various biological and phar-
macological activity data as well as structure-activity re-
lationships have been accumulated on paclitaxel and
its congeners (taxoids) [10–12]. The structural biology
investigation into the paclitaxel-tubulin interactions has
culminated in the determination of the electron crystal-
lographic (EC) structure of the α,β-tubulin heterodimer
bound to paclitaxel at 3.7 Å resolution and its subse-
quent refinement to 3.5 Å resolution [13, 14]. Although
representing a seminal achievement, this EC structure*Correspondence: iojima@notes.cc.sunysb.edulacks the atomic resolution necessary to ascertain the
structure of paclitaxel in the β-tubulin binding pocket
and the intermolecular interactions responsible for the
stabilizing effect of the drug on microtubules.
Solution [15] and solid-phase [16, 17] NMR studies,
photolabeling studies [18–20], as well as computational
modeling [21–23] have provided additional information
regarding the binding structure of paclitaxel. A set of
computational protocols described below has been de-
veloped in order to unify these highly valuable pieces
of information into a more detailed description of the
tubulin binding mode of paclitaxel and its analogs.
Synthetic approaches to paclitaxel analogs bearing
built-in conformational restrictions have produced the
analogs with intrinsically constrained C-13 side chains
[24] and the analogs with macrocyclic constraints link-
ing the C-2 and C-3# positions [21, 25, 26], the C-2 and
C-3#N positions [27], as well as the C-4 and C-3# posi-
tions [28]. The syntheses and biological evaluations of
these conformationally restricted paclitaxel analogs
were performed to identify the bioactive structure of
paclitaxel, which may form the basis for the rational
design of new generation paclitaxel-like anticancer
agents with much simplified structures. However, until
very recently [29], none of these restrained analogs dis-
played in vitro activities equal or superior to paclitaxel.
Accordingly, we had a valid concern about the rele-
vance of applying an enzyme-inhibitor complex-type
medicinal chemistry approach to the drug-protein in-
teraction involving the highly sophisticated tubulin-
microtubule dynamics [8, 9, 30] while we could not
obtain a highly active constrained paclitaxel analog.
Nevertheless, we did find an analog that exhibited
equal or better activity in the tubulin polymerization as-
say as compared to paclitaxel.
While our computational study was in progress for
this highly active analog, Snyder, Kingston, and co-
workers reported their results along the same line of
research. Their work prompted us to report here our
studies on the β-tubulin binding site model for pacli-
taxel and taxoids on the basis of a new molecular mod-
eling protocol involving the induced-fit of the protein
upon drug binding as well as the design, synthesis, and
biological activity evaluations of a conformationally re-
strained paclitaxel analog. The results strongly support
the utility of considering the tubulin bound conforma-
tion as the bioactive structure of paclitaxel and its use
for further rational drug design.
Results and Discussion
Derivation of a Refined Paclitaxel Binding
Site Model of -Tubulin
Conformation of Paclitaxel in b-Tubulin
Solution [15, 31–33] NMR spectroscopy and X-ray crys-
tallography [2, 34] of paclitaxel and its analogs have
provided rich information about the various conforma-
tions paclitaxel can adopt in the unbound state. This
information is only of limited use, since ligands com-
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340Figure 1. Structures
Structures of paclitaxel, docetaxel, photoaffinity probe [3H]7-BzDc-paclitaxel, and conformationally constrained taxoids SB-T-14801 and SB-
T-2053. 2-FB-PT is also shown with intramolecular REDOR-NMR distances indicated.monly undergo large conformational changes upon G
Tbinding to their targets [35].
Recently, a fluorinated taxoid, 2-(p-fluorobenzoyl)- m
lpaclitaxel (2-FB-PT), was used bound to microtubules
in solid state 13C{15N or 19F}-double-REDOR-NMR ex- s
iperiments [17]. After 3 months of data acquisition,
Schaefer and his collaborators were able to determine (
ltwo 13C-19F intramolecular distances for 2-FB-PT in the
bound state (d1 and d2 in Figure 1). T
cMolecular dynamics (MD) simulations were initially
conducted on 2-FB-PT in vacuo at increasing temper- t
hatures from 300K to 500K (InsightII 2000, Accelrys,
CVFF force field). Unfortunately, some side-chain p
obonds (e.g., C2#-C3#) of the molecule present a high-
energy barrier to rotation, impeding adequate sam- p
tpling. For this reason, we switched to a Monte Carlo
(MC) conformational search [36]. The two intramolecu- f
elar distances determined were then used as constraints
in an extensive MC conformational search on 2-FB-PT p
nin vacuo (Macromodel 6.5, Schrödinger, Inc., MM3*
forcefield). Conformational diversity in a set of resultant s
aminimized structures was assessed by performing a
cluster analysis on the 1371 retained conformations r
rwith energies within 50 kJ/mol of the global minimum
(Xcluster, Schrödinger, Inc.). Sixteen clusters were a
tformed according to the values of 10 dihedral angles of
the C13 and C2 side chains. A representative structure m
bfor each cluster is shown in Figure 2. Remarkably, most
of these structures have their C3# benzamido moiety c
cpointing in the same direction as the C2 fluorobenzoate
group, as seen for docetaxel in its X-ray structure [2]. l
sAlso, to accommodate the REDOR-NMR geometric
requirements, the entire C13 side chain has to move
faway from the C2 fluorobenzoate, unlike in the “hy-
drophobic collapse” conformation observed for the free C
Ndrug [31–33].
It should be noted that preliminary unrestrained mo- a
flecular dynamics simulations on 2-FB-PT (even at ele-
vated temperature, allowing rotation around the C2#- t
lC3# bond) showed that very few conformations could
respect both REDOR distance ranges. cuided Docking of Taxoids in b-Tubulin
he exact orientation of paclitaxel in β-tubulin has been
uch debated [17, 20]. Some agreement was neverthe-
ess found between the electron crystallographic den-
ity and three photoaffinity labeling experiments [20]. It
s worth mentioning that a C7-benzodihydrocinnamoyl
C7-BzDC) derivative of paclitaxel (Figure 1) exclusively
abeled the Arg282 residue in the M loop of β-tubulin.
his specificity prompted us to model the covalent
omplex thus formed as a single molecule. This way,
ranslational and rotational motions of the ligand are
ampered, while the ligand evolves in its most likely
osition. A two-step procedure was then adopted in
rder to get a refined binding site model. First, the com-
lex formed by β-tubulin and the bound C7-BzDc pacli-
axel in the possible bioactive conformation inferred
rom the Monte Carlo conformational search was mod-
led and minimized. The carbonyl carbon of the benzo-
henone moiety (i.e., as α-hydroxy radical) was con-
ected to the α-carbon of Arg282, since the excited
tate of the benzophenone moiety would selectively
bstract hydrogen from the α position of an amino acid
esidue because of the capto-dative stabilization of the
esulting radical species [37]. The peptide backbone
toms of the protein were kept fixed at all times during
he simulation, while side-chain atoms were free to
ove, allowing the reorganization of side chains upon
inding of modified taxoids (partial induced fit). After
leavage of the BzDc linker, a free ligand binding site
omplex comprising only residues within 10 Å of any
igand or linker atom was minimized again under the
ame conditions.
The procedure was applied to paclitaxel, starting
rom all 16 conformations retained from the Monte
arlo conformational search of 2-FB-PT. The REDOR-
MR distances were verified after docking and used as
filter to determine the tubulin bound paclitaxel con-
ormation. However, none of the representative struc-
ures could strictly maintain both distances in the al-
owed REDOR-NMR ranges after docking. Two factors
ould contribute to this: (1) the availability of large
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341Figure 2. REDOR-NMR Constrained Monte
Carlo Conformational Search on 2-FB-PT
Representative structures of the 16 confor-
mational clusters.empty spaces in the binding site and (2) the fact that
the REDOR distances were derived from MTBs, while
the EC structure corresponds to the Zn-sheet form of
tubulin, which might present some structural differ-
ences to the MTB form. The structure deviating the
least from the two REDOR-NMR restraints (i.e., d1 =
9.97 Å, d2 = 9.38 Å) was selected as our tubulin bound
paclitaxel structure, “REDOR-taxol” (Figure 3).
A significant asset of this guided docking protocol is
the total flexibility of the protein side chains during the
minimization stages. This allows docking of heavily
modified or bulky taxoids under the assumption that
their baccatin skeleton remains in the vicinity of pacli-
taxel in the binding pocket. Figure 4 shows an example
of a tubulin bound macrocyclic paclitaxel analog, SB-
T-14801, a surprisingly active analog in its series (IC50
60 nM against LCC6) [38]. The protein shows extensive
rearrangements induced by the connection of the C2
and C13 taxoid side chains: in particular, the His227 side
chain has to rotate and face the C2 benzoyl group of
the taxoid, confirming that even partial flexibility of the
protein allows the binding site to accommodate bulk-
ier analogs.
Analysis of Paclitaxel Binding Site Models
While preliminary results of this work were obtained,
producing the “REDOR-taxol” structure [53], Snyder et
al. reported a binding site model for paclitaxel by dock-
ing 26 experimentally observed unbound paclitaxel
conformers into the Zn-sheets EC density map [22]. Al-though this approach also resulted in an extended bi-
oactive conformation for paclitaxel, “T-taxol,” the
resolution of the EC map appears insufficient for un-
equivocal selection of the optimal binding conforma-
tion of paclitaxel. It is worth pointing out that T-taxol
does not comply with the REDOR-NMR distances, with
values of 8.11 Å and 9.32 Å for d1 and d2, respectively
(measured on 2-FB-PT in the T-taxol conformation),
showing that, in T-taxol, the C-2 and C-3# side chains
are more collapsed than those found with the REDOR-
NMR experiment.
The main difference between Snyder’s T-taxol and
our REDOR-taxol is the conformation of the C13 side
chain. In order to fairly compare REDOR-taxol to T-taxol,
we docked the T-taxol structure into the β-tubulin bind-
ing site using our guided docking protocol (see above).
This procedure caused a small but significant realign-
ment of the T-taxol conformation, and an overlay of the
resulting pose with REDOR-taxol is shown in Figure 3.
The two models locate their C-3# phenyl rings in nearly
identical loci. However, the C2#-hydroxyl group, which
usually forms an intramolecular H bond with the C1#-
carbonyl oxygen in the free drug, is pointed toward
His227 in the REDOR-taxol structure, forming a very
buried H bond of increased strength. This makes a
sharp contrast to the more solvent-exposed H bond be-
tween the C2#-hydroxyl and the backbone carbonyl ox-
ygen of Arg359 in the T-taxol binding pose.
Additionally, the internal energy of the “free form” of
Chemistry & Biology
342Figure 3. Proposed β-Tubulin Binding Models of Paclitaxel
(A) Overlay of the docked REDOR-taxol (green) and T-taxol (yellow) structures.
(B) Overlay of REDOR-taxol (green) with SB-T-2053 (blue). The overlay is performed by matching the protein backbone, which is kept fixed
during docking.tor design methodology, we set off to introduce confor- t
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fFigure 4. Docked Complex of SB-T-14801paclitaxel detached from tubulin in vacuo is w42 kJ/ m
tmol lower in the REDOR-taxol conformation than in the
T-taxol conformation (CVFF force field, InsightII). This s
tenergy difference mostly arises from torsional terms
and would suggest that REDOR-taxol requires less sta- f
Cbilization from the protein to make the overall associa-
tion favorable. t
THowever, due to the low resolution of the tubulin EC
density map, direct experimental evidence is lacking to b
vconfirm or rule out one of these two conformations as
the bioactive form, assuming it is unique. b
c
TDesign and Synthesis of Conformationally
Restrained Macrocyclic Taxoids l
tUpon visualizing the paclitaxel binding site model of
β-tubulin, we noticed unoccupied spaces around the t
rpaclitaxel structure. Following a typical enzyme-inhibi-ational constraints to lower the conformational en-
ropy loss upon binding. These structural modifications
hould cause minimal disruption to the binding interac-
ions in filling in the empty volumes and possibly add
urther stabilizing interactions with the protein.
onformational Restriction
o the Binding Conformation
he docked REDOR-taxol structure disclosed a possi-
ility of inserting a hydrophobic linking moiety in the
ast hydrophobic cluster formed by the C3#N and C2
enzoyl groups and the imidazol moiety of His227. Ac-
ordingly, we designed a C14-C3#N-linked taxoid, SB-
-2053 (Figure 1), in which a short (five atoms) linker
ocks the C3#N side chain in an unequivocal conforma-
ion close to REDOR-taxol. Inserting a linker between
he C14 and C3#N positions also presents only a small
isk of disrupting the original binding of the drug, since
he linker moiety lies toward the solvent-exposed sur-
ace of the binding site and hence should not generate
nfavorable contacts with the protein.
In order to measure the level of conformational re-
triction imposed, we conducted a Monte Carlo confor-
ational search on SB-T-2053 in a simulated aqueous
nvironment. Performing the same calculation on pacli-
axel provided a reference state from which the pertur-
ation can be assessed. Our attention focused on the
-13 side chain dihedral angles since they should be
he ones most affected by the introduction of the con-
traint. Figure 5 shows the dihedral angle distributions
or both SB-T-2053 and paclitaxel and compares those
o the reference values of REDOR-taxol and T-taxol.
he C13-O13 torsion angle remains quite distributed in
B-T-2053, covering the same range as paclitaxel with
urprisingly low propensity for the −105° and −150°
eaks seen for paclitaxel. The next torsion angle,
round O13-C1#, is for the ester linkage and is mostly
entered on 0°. However, paclitaxel in solution also
dopts the reversed conformation (i.e., 180°) to a lesser
xtent, contrary to SB-T-2053. The last two dihedral an-
les, around C1#-C2# and C2#-C3#, are where the most
lexibility is observed in paclitaxel. Indeed, except for
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343Figure 5. Conformational Diversity in Constrained Taxoid SB-T-2053
Comparison of the C-13 side-chain dihedral angle distributions for paclitaxel (brown) and SB-T-2053 (red) in water. The reference values for
REDOR-taxol (blue) and T-taxol (green) are indicated by vertical lines.the 90° to 150° region, the O13-C1#-C2#-O2# dihedral
angle can adopt every value, with peaks at 10°, −30°,
−75°, −120°, and −165°. In sharp contrast, SB-T-2053
does not show any density between 0° and 90°. In the
50 kJ/mol energy range scrutinized, no SB-T-2053
structure was detected that matched REDOR-taxol or
T-taxol. However, a peak of the probability density ex-
ists near each of the two reference conformations at
−15° and −150°. In addition, the T-taxol value should be
quite unfavorable since it corresponds to a fully eclipsed
conformation.
The O2#-C2#-C3#-N3# dihedral angle distribution
shows the most striking effects of the conformational
constraint: while paclitaxel exists in four major confor-
mations, SB-T-2053 is restricted to only two, each of
them reproducing the value observed in either REDOR-
taxol (176°) or T-taxol (-67°). Therefore, we conclude
that the constraint introduced is quite effective in re-
stricting conformational diversity while enriching the
solution ensemble in bioactive conformations.
Additionally, very little reorganization of protein side
chains is observed after docking of SB-T-2053 as com-
pared to REDOR-taxol (Figure 3), confirming the benign
nature of our perturbation on intermolecular interac-
tions.
Synthesis of SB-T-2053
We employed the ring-closing metathesis (RCM) [39] as
the key reaction for the synthesis of SB-T-2053 based
on our previous successful applications of this protocol
in constructing the C2-C3#-linked [21, 25] and C2-C3#N-linked [27] macrocyclic taxoids. The diene pre-
cursor for RCM was synthesized through the highly effi-
cient β-lactam-baccatin ring-opening coupling protocol
[40–42].
The C-13 side-chain precursor of SB-T-2053, β-lac-
tam 7, was prepared as shown in Figure 6. β-Lactam 5
[43] was treated with 2-allylbenzoyl chloride 6 [44] to
give the desired β-lactam 7 in 91% yield.
In order to construct the C14-C3#N linkage, we intro-
duced an olefin moiety at the C14 position of baccatin.
This was realized by allylation of 14β-hydroxy-7-TES-bac-
catin (4) derived from naturally occurring 14β-hydroxy-10-
deacetylbaccatin (14β-OH-10-DAB, 1) [45]. As Figure 6
shows, baccatin 1 was first treated with acetic anhy-
dride in the presence of cerium chloride to afford 10-
Ac-14β-OH-10-DAB 2. Then, selective TES protection
of the C7-OH using TESCl and imidazole gave 7-TES-
14-OH-baccatin (3) in 83% yield over two steps. Finally,
in the presence of NaHMDS, 3 was treated with allyl
iodide to afford 4 bearing an allyl ether moiety at the
C-14 position. The ring-opening coupling of β-lactam 7
with baccatin 4 gave diene 8 in 72% yield. RCM reac-
tion afforded the desired macrocyclic taxoid 9 in 85%
yield. Finally, the silyl groups were removed using HF-
pyridine to yield SB-T-2053 (E-isomer only).
Biological Evaluation of Conformationally
Constrained Taxoid SB-T-2053
The activities of SB-T-2053 and paclitaxel were com-
pared in an in vitro tubulin polymerization assay.
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344Figure 6. Synthesis of C14-C3#N Linked Taxoid SB-T-2053Changes in absorbance in this assay indicate the ex- p
atent of microtubule polymerization. SB-T-2053, like
paclitaxel, induces tubulin polymerization in the ab- A
psence of GTP, which is normally required for microtu-
bule assembly. Furthermore, the microtubules formed c
pin the presence of SB-T-2053 and paclitaxel were both
stable against calcium-induced depolymerization (see
Figure S1). The calculated critical concentration of pro- S
tein required to achieve assembly is approximately 0.08
mg tubulin/ml for both drugs (data not shown). As indi- A
hcated in Figures 7A and 7B, both drugs polymerize tu-
bulin to a similar extent over a range of different ratios t
Nof tubulin to drug. Furthermore, a competitive binding
assay indicated that both paclitaxel and SB-T-2053 ef- b
tfectively displace [3H]paclitaxel from microtubules (see
Figure S2). This result provides further strong support- t
bing evidence that SB-T-2053 binds to the paclitaxel
binding site on the microtubule. H
bThe macrocyclic taxoid SB-T-2053 also exhibits
strong potency against LCC6-WT and MCF-7 human l
abreast cancer cell lines with IC50 values of 15 and 42
nM, respectively (Figure 7C). The former growth inhibi- C
ttion is only 3.3 times less potent than paclitaxel against
the same cell line. Considering that SB-T-2053 is com- p
iparable to paclitaxel as an inducer of microtubule poly-
merization, the small differences in IC values between p50aclitaxel and SB-T-2053 could be due to cell perme-
bility and solubility factors of two distinct molecules.
lso, SB-T-2053 exhibits the same level of potency as
aclitaxel against multidrug-resistant human breast
ancer cell lines (LCC6-MDR and MCF7-R) overex-
ressing P-glycoprotein [46, 47].
ignificance
new bioactive structure of paclitaxel, REDOR-taxol,
as been identified on the basis of detailed computa-
ional analysis of the combined data from REDOR-
MR, electron crystallography, and photoaffinity la-
eling experiments. Although the REDOR-taxol struc-
ure shares similar features with Snyder’s T-taxol [22],
he REDOR-taxol structure allows a strong H bonding
etween the C2 hydroxyl group of paclitaxel and the
is227 residue, in contrast to T-taxol, which has H
onding between C2-OH and Arg359 in the S9-S10
oop. The REDOR-taxol structure was used to design
conformationally constrained taxoid, wherein the
3N-pharmacophoric group is restrained directly to
he C14 of the baccatin skeleton with little or no im-
act on other key pharmacophoric groups and caus-
ng minimal unfavorable interactions with the target
rotein. We have successfully synthesized SB-T-
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345Figure 7. Compared In Vitro Bioactivities of
SB-T-2053 and Paclitaxel
(A and B) Tubulin polymerization and micro-
tubule stabilization assay for 5 µM paclitaxel
or SB-T-2053 and various concentrations of
tubulin (A), 5 mg/ml tubulin and various con-
centrations of drug (B).
(C) Growth inhibition assay IC50 values, nM
(concentration of compound inhibiting 50%
of the growth of human tumor cell line after
72 hr drug exposure); LCC6-WT, human breast
carcinoma; LCC6-MDR, MDR1 transducedline;
MCF7-S, human breast carcinoma; MCF7-R,
MDR phenotype human breast carcinoma.2053, a C14-C3N-linked macrocyclic taxoid using
RCM in the key step. Molecular modeling anticipates
decreased conformational flexibility for the C13 side
chain of SB-T-2053 while still allowing the adoption of
either REDOR-taxol or T-taxol conformation.
The macrocyclic taxoid SB-T-2053 possesses sig-
nificant potency against human breast cancer cell
lines comparable to that of paclitaxel. Moreover, SB-
T-2053 induces tubulin polymerization in vitro at least
as well as paclitaxel, which directly validates our de-
sign process.
This example of successful conformational restric-
tion corroborates the very recent report by Snyder,
Kingston, and their collaborators, wherein C4-C3-
phenyl-linked analogs of paclitaxel were shown to be
at least as active as paclitaxel against cancer cell
lines as well as in tubulin binding and tubulin-poly-
merization assays [29]. These highly encouraging re-
sults obtained by us and others have opened a new
avenue for drug design and discovery of new-genera-
tion taxoids as well as new microtubule-stabilizing
agents based on the refined structural information of
drug-protein complexes in accordance with a typical
enzyme-inhibitor medicinal chemistry approach.
Experimental Procedures
Computational Methods
2-FB-PT was modeled after the X-ray structure of paclitaxel [34] in
Macromodel 6.5 (Schrödinger) by substituting an F atom on the
para position of the C2 benzoate group. Monte Carlo conforma-
tional searching was conducted with energy minimization on the
isolated 2-FB-PT molecule in the gas phase (4000 MC steps, mini-
mization for 1000 steps with Polak-Ribiere conjugated gradients)
using the MM3* force field, well suited for the conformational analy-
sis of small molecules. All side-chain rotatable bonds were allowed
to vary. 1371 structures were found within 50 kJ/mol, which com-plied with both REDOR NMR distances. These conformers were
clustered according to their C13 and C2 side chains’ dihedral an-
gles using the Xcluster facility packaged with Macromodel 6.1. Six-
teen clusters were obtained at the 1356 clustering level, comprising
124, 250, 76, 236, 1, 129, 243, 220, 69, 1, 1, 1, 2, 1, 1, and 16
members, respectively. A representative structure for each cluster
was selected as the structure with minimal root-mean-square dis-
tance to the centroid of all cluster members, regardless of its en-
ergy relative to the global minimum of the conformational search.
All 16 representative conformations of paclitaxel were then
docked into the paclitaxel binding site of β-tubulin following the
same procedure: their taxane skeleton (carbon atoms of the A, B,
and C rings) was overlaid with those of docetaxel present in the
deposited β-tubulin EC structure (Protein Data Bank ID code
1TUB). The BzDc linker was modeled and attached to C7 of pacli-
taxel in InsightII 2000 (Accelrys Inc.). Finally, the linker was at-
tached to the Cα of Arg282 by merging the two fragments, thus
creating an elongated C-C bond.
The molecular complex was allowed to minimize for 1000 steps
with the conjugate gradients method, CVFF force field, and dis-
tance-dependent dielectric. The BzDc linker was then erased, and
H atoms were added to reconstitute the free paclitaxel ligand and
the protein after a binding domain comprising all residues within
10 Å of the bound 7-BzDc-PTX had been defined. A second minimi-
zation was then conducted on the noncovalent complex of pacli-
taxel with this 10 Å binding domain (same conditions as first mini-
mization). The approach was identical for all the taxoids docked.
Monte Carlo conformational searches on paclitaxel and SB-T-
2053 were performed in Macromodel 6.5 using a generalized born
with surface area term (GBSA) continuum solvent description of
water solvation [48]. Other conditions were identical to the 2-FB-
PT MC conformational search, except that no distance restraint
was used.
Tubulin Polymerization Assay
Assembly and disassembly of calf brain microtubule protein (MTP)
was monitored spectrophotometrically (Beckman Coulter DU 640,
Fullerton, CA) by recording changes in turbidity at 350 nm at 37°C
[49, 50]. MTP was diluted to 1 mg/ml in MES buffer containing 3 M
glycerol. The concentration of tubulin in MTP was 85%, and that
was taken into consideration when the ratios of tubulin to drug
Chemistry & Biology
346were presented in Figures 7A and 7B. Microtubule assembly was d
cdone with 5 µM paclitaxel or SB-T-2053 and various concentrations
of tubulin or with 5 mg/ml tubulin and various concentations of p
drug. Calcium chloride (6 mM) was added to the assembly reaction
after 90 min to follow the calcium-induced microtubule depolymeri-
7zation.
T
a
Competitive Binding Assay t
[3H]paclitaxel (specific activity 19.3Ci/mmol, 15.89 µM in toluene) t
was dried and dissolved with cold paclitaxel in dimethyl sulfoxide t
to a final concentration of 500 µM. [3H]paclitaxel, different concen- E
trations of the competing compounds, or dimethyl sulfoxide was 2
added to MTP (2 µM) in MES buffer containing 0.2 mM GTP. After T
incubation for 2 hr at 37°C, samples were layered onto 5% sucrose a
in MES buffer with 3 M glycerol and centrifuged in a Ti42.2 rotor in s
a Beckman L7 ultracentrifuge (Beckman Instruments, Inc., CA) at M
100,000 × g for 1 hr at 27°C. After centrifugation, the supernatant 3
was carefully removed. The pellet was washed three times with (
MES buffer and dissolved in 10 mM sodium phosphate buffer con- (
taining 1% SDS. Radioactivity was determined in a liquid scintilla- 6
tion counter (PerkinElmer, IL). Protein concentration was measured H
by DC Protein Assay (Bio-Rad Laboratories, CA). After correcting H
for small amounts of nonspecifically sedimented protein, the ratio 6
between [3H]paclitaxel and tubulin dimer was calculated. 8
1
In Vitro Growth Inhibition Assay 7
Tumor-cell growth inhibition was determined according to the 1
method established by Skehan et al. [51]. Human breast carcinoma C
cells MCF-7, LCC6, and their Pgp-expressing variants, MCF7-R
and LCC6-MDR, were plated at a density of 400–2000 cells/well in
196-well plates and allowed to attach overnight. These cell lines
Twere maintained in RPMI-1640 medium (Roswell Park Memorial In-
Nstitute growth medium) supplemented with 5% fetal bovine serum
mand 5% Nu serum (Collaborative Biomedical Product, MA). Taxanes
mwere solubilized in DMSO and further diluted with RPMI-1640 me-
sdium. Triplicate wells were exposed to various treatments. After 72
(hr incubation, 100 µl of ice-cold 50% trichloroacetic acid (TCA) was
oadded to each well, and the samples were incubated for 1 hr at
s4°C. Plates were then washed five times with water to remove TCA
pand serum proteins, and 50 µl of 0.4% sulforhodamine B (SRB) was
eadded to each well. Following a 5 min incubation, plates were
1
rinsed five times with 0.1% acetic acid and air dried. The dye was
Hthen solubilized with 10 mM Tris base (pH 10.5) for 5 min on a
3gyratory shaker. Optical density was measured at 570 nm. The IC50
Jvalues were then calculated by fitting the concentration-effect
(curve data with the sigmoid-Emax model using nonlinear regression
(weighted by the reciprocal of the square of the predicted ef-
Nfect [52].
2
7General Synthetic Procedures
1Chemicals and reagents were purchased from Sigma-Aldrich or
NFisher Scientific and were used without further purification unless
otherwise noted. 14β-hydroxy-10-deacetylbaccatin III was a gift
from Indena, SpA and used as received. Solvents were reagent (
grade and freshly distilled under nitrogen before use. 1H and 13C O
NMR spectra were measured on a Bruker AC-250 NMR spectrome- T
ter or Varian 300, 400, 500 NMR spectrometers using tetramethylsi- m
lane as the internal standard. Melting points were measured on a a
Thomas Hoover Capillary melting point apparatus and are uncor- t
rected. Optical rotations were measured on a Perkin-Elmer Model a
241 polarimeter. TLC was performed on Merck DC-alufolien with N
Kieselgel 60F-254, and column chromatography was carried out on a
silica gel 60 (Merck; 230–400 mesh ASTM). High-resolution mass d
spectra were obtained from the Mass Spectrometry Laboratory, p
University of Illinois at Urbana-Champaign, Urbana, IL. e
(
614-Hydroxybaccatin III (2)
To a solution of 14β-hydroxy-10-deacetylbaccatin III (1) (200 mg, J
(0.37 mmol) in 13 ml of THF was added CeCl3.7H2O (16 mg, 0.037
mmol) and acetic anhydride (0.5 ml, 3.7 mmol). The reaction mix- N
1ture was then stirred 2 hr at room temperature and quenched with
a saturated aqueous NaHCO3 solution (10 ml). The mixture was 1
Cthen extracted with EtOAc (30 ml × 3), washed with brine (15 ml),ried over anhydrous MgSO4, and concentrated in vacuo. The
rude product was used directly for the next step without further
urification as a white solid (256 mg).
-Triethylsilyl-14-Hydroxybaccatin III (3)
o a solution of 14β-hydroxybaccatin III (2) (222 mg, 0.37 mmol)
nd imidazole (98 mg, 1.08 mmol) in DMF (5 ml) was added chloro-
riethylsilane (0.18 ml, 1.08 mmol) dropwise via syringe at room
emperature. The reaction mixture was then stirred for 5 hr at room
emperature, quenched by saturated NH4Cl, and extracted with
tOAc (30 ml × 3). The mixture was then washed with H2O (10 ml ×
), brine (10 ml), dried over anhydrous MgSO4, and concentrated.
he crude product was purified on a silica gel column using hex-
nes/EtOAc (2/1 followed by 1/1) as the eluent to give 3 as a white
olid (219 mg, 83% over 2 steps). Mp 164°C –166°C. 1H NMR (300
Hz, CDCl3) δ 0.58 (m, 6 H), 0.91 (m, 9 H), 1.02 (s, 3 H), 1.22 (s,
H), 1.68 (s, 3 H), 1.86 (m, 1 H) (H6a), 2.14 (s, 3 H), 2.17 (s, 3 H)
OAc), 2.28 (s, 3 H) (OAc), 2.50 (m, 1 H) (H6b), 3.26 (br s, 1 H), 3.61
s, 1 H), 3.79 (br s, 1 H), 3.80 (d, J = 7.2 Hz, 1 H) (H3), 4.01 (d, J =
.3 Hz, 1 H) (H14), 4.16 (d, J = 8.3 Hz, 1 H) (H20a), 4.24 (d, J = 8.3
z, 1 H) (H20b), 4.46 (dd, J = 6.5, 10.3 Hz, 1 H) (H7), 4.67 (d, J = 5.5
z, 1 H), 4.93 (d, J = 8.7 Hz, 1 H) (H5), 5.78 (d, J = 7.2 Hz, 1 H) (H2),
.43 (s, 1 H) (H10), 7.41 (t, J = 7.5 Hz, 2 H), 7.55 (t, J = 7.5 Hz, 1 H),
.02 (d, J = 7.4 Hz, 2 H). 13C NMR (62.9 MHz, CDCl3) δ 5.2, 6.7, 10.0,
4.6, 20.8, 21.8, 22.3, 26.2, 37.1, 42.8, 46.5, 58.6, 72.2, 74.1, 74.3,
5.5, 76.3, 76.7, 80.7, 84.1, 128.6, 129.3, 133.5, 141.3, 165.4, 169.3,
70.3, 202.3. HRMS (FAB/DCM/NaCl) m/z calculated for
37H52O12SiH+: 717.3306, found: 717.3276.
4-Allyl-7-Triethylsilyl-14-Hydroxybaccatin III (4)
o a solution of 3 (63 mg, 0.09 mmol) in DMF (3 ml) was added
aHMDS (1.0 M in THF, 0.1 ml, 0.1 mmol) at −40°C. The reaction
ixture was stirred for 5 min, and then allyl iodide (0.012 ml, 0.1
mol) was added. The reaction was quenched after 1 hr with a
aturated aqueous NH4Cl solution (20 ml) and extracted with EtOAc
30 ml × 3) and washed with H2O (10 ml × 2) and brine (10 ml). The
rganic layer was dried over anhydrous MgSO4, filtered, and the
olvent was removed under reduced pressure. The residue was
urified on a silica gel column using hexanes/EtOAc (5/1) as the
luent to afford 4 as a white solid (74 mg, 82%). Mp: 133°C–135°C.
H NMR (300 MHz, CDCl3) δ 0.55 (m, 6 H), 0.90 (m, 9 H), 1.19 (s, 3
), 1.60 (m, 2 H), 1.66 (s, 3 H), 1.84 (m, 1 H), 2.00 (m, 3 H), 2.12 (s,
H), 2.29 (s, 3 H), 2.50 (m, 1 H), 3.22 (d, J = 4.2 Hz, 1 H), 3.69 (d,
= 5.7 Hz, 1 H), 3.77 (m, 2 H), 4.06 (m, 1 H), 4.18 (m, 1 H), 4.29-4.47
m, 3 H), 4.69 (bs, 1 H), 4.87–4.98 (m, 3 H), 5.61–5.72 (m, 1 H), 5.83
d, J = 6.9 Hz, 1 H), 7.42 (m, 2 H), 7.55 (m, 1 H), 8.06 (m, 2 H). 13C
MR (62.9 MHz, CDCl3) δ 5.1, 5.4, 6.6, 6.7, 9.7, 10.0, 14.7, 20.8,
1.4, 22.4, 26.2, 37.1, 42.7, 46.4, 58.7, 72.1, 73.0, 74.5, 75.6, 75.7,
6.2, 76.4, 80.9, 81.5, 82.0, 84.0, 117.4, 128.4, 129.7, 129.8, 133.3,
33.6, 133.7, 141.2, 165.6, 169.3, 170.1, 201.9. HRMS (FAB/DCM/
aCl) m/z calculated for C40H56O12SiH+: 757.3619, found: 757.3643.
3R,4S)-1-(2-Allylbenzoyl)-3-Triethylsilyloxy-4-Phenylazetidin-2-
ne (7)
o a solution of β-lactam 5 (60 mg, 0.216 mmol), triethylamine (0.13
l, 0.912 mmol), and DMAP (7 mg, 0.06 mmol) in 2.4 ml CH2Cl2 was
dded 2-allylbenzoyl chloride in CH2Cl2 (2 ml) dropwise at room
emperature. The mixture was stirred overnight at room temper-
ture, and the reaction was quenched with a saturated aqueous
H4Cl solution (20 ml). The mixture was then extracted with ethyl
cetate (30 ml × 3). The combined extracts were dried over anhy-
rous MgSO4 and concentrated in vacuo. The crude product was
urified on a silica gel column using hexanes/EtOAc (25/1) as the
luent to afford 7 as a colorless oil (97 mg, 91% yield): 1H NMR
400 MHz, CDCl3) δ 0.42 (m, 6 H), 0.77 (m, 9 H), 3.48 (dd, J = 15.6,
.0 Hz, 1 H), 3.58 (dd, J = 15.6, 6.4 Hz, 1 H, 5.01 (m, 2 H), 5.14 (d,
= 6.4 Hz, 1 H), 5.33 (d, J = 17.5, 6.4 Hz, 1 H), 5.93 (m, 1 H), 7.30
m, 7 H), 7.4 (dd, J = 8.8, 6.8 Hz, 1 H), 7.57 (d, J = 6.8 Hz, 1 H), 13C
MR (100.5 MHz, CDCl3) δ 4.3, 6.2, 37.2, 61.3, 76.7, 115.9, 125.9,
28.0, 128.1, 128.3, 128.8, 130.2, 131.4, 133.1, 133.6, 136.9, 138.9,
65.4, 166.6. HRMS (FAB/DCM/NaCl) m/z calculated for
H NO SiH+: 422.2151, found: 422.2153.25 31 3
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34714-Alloxy-3N-Debenzoyl-3N-(2-Allylbenzoyl)-7,2-
Triethylsilylpaclitaxel (8)
To a solution of 4 (20 mg, 0.026 mmol) and β-lactam 7 (33 mg, 0.079
mmol) in THF (2.8 ml) was added LiHMDS (0.04 ml, 0.04 mmol) at
−40°C. The reaction mixture was warmed up to −20°C over 3 hr
and then quenched with a saturated aqueous NH4Cl solution and
extracted with EtOAc. The organic layers were combined and
solvent was removed under reduced pressure. The residue was
purified by chromatography (eluent Hex/EtOAc, 7/1) to afford 8 as
a white solid. (22 mg, 72%). Mp: 99°C –102°C. 1H NMR (500 MHz,
CDCl3) δ 0.35–0.47 (m, 6 H), 0.55–0.63 (m, 6 H), 0.79 (m, 9 H), 0.93
(m, 9 H), 1.15 (s, 3 H), 1.26 (s, 3 H), 1.74 (s, 3 H), 1.91 (m, 1 H), 2.03
(s, 3 H), 2.19 (s, 3 H), 2.57 (m, 1 H), 2.58 (s, 3 H), 3.43 (dd, J = 16.0,
5.5 Hz, 1 H), 3.53 (dd, J = 16.0, 5.5 Hz, 1 H), 3.66 (s, 1 H), 3.82 (d,
J = 7.5 Hz, 1 H), 3.84 (d, J = 8.0 Hz, 2 H), 3.91 (dd, J = 10.5, 6.5 Hz,
1 H), 4.28 (d, J = 9.0 Hz, 1 H), 4.32 (dd, J = 10.5, 4.0 Hz, 1 H), 4.47
(m, 3 H), 4.62 (d, J = 10.5 Hz, 1 H), 4.71 (d, J = 1.5Hz, 1 H), 4.90 (dd,
J = 17.0, 2.0 Hz, 1 H), 4.99 (m, 2 H), 5.44 (m, 1 H), 5.57 (d, J = 8.4
Hz, 1 H), 5.99 (m, 2 H), 6.20 (d, J = 7.0 Hz, 1 H), 6.47 (s, 1 H), 6.99
(d, J = 8.5 Hz, 1 H), 7.24 (m, 2 H), 7.40 (m, 8 H), 7.57 (t, J = 8.0 Hz,
1 H), 8.10 (d, J = 7.5 Hz, 2 H); 13C NMR (100.5 MHz, CDCl3) δ 4.6,
5.5, 6.7, 6.9, 10.1, 14.6, 21.1, 23.6, 26.3, 37.5, 43.7, 46.1, 56.2, 59.0,
72.5, 72.8, 75.0, 75.2, 76.7, 76.8, 78.8, 78.9, 81.9, 84.4, 113.8, 116.3,
118.1, 126.6, 126.7, 127.9, 128.2, 128.9, 129.2, 129.8, 130.2, 130.6,
130.8, 133.0, 133.7, 134.5, 135.6, 135.9, 136.5, 137.8, 138.6, 138.8,
138.9, 165.8, 169.1, 169.6, 169.9, 171.7, 201.2. HRMS calculated for
C65H87NO15Si2H+: 1178.5693, found 1178.5703.
Macrocyclic Taxoid SB-T-2053
To a solution of 8 (47 mg, 0.041 mmol) in 23 ml CH2Cl2 was added
bis(tricyclohexylphosphine)benzylideneruthenium(IV) dichloride
(“Grubbs’s catalyst,” 8 mg, 0.01 mmol) in 0.2 ml CH2Cl2. The reac-
tion was stirred overnight. Solvent was removed under reduced
pressure. The residue was passed through a short column (eluent
Hex/EtOAc, 5/1) to remove remaining catalyst and afford 9 as a
crude yellow solid (39 mg, 85%).
To a solution of 9 (50 mg) in CH3CN (1.0 ml) and pyridine (1.0 ml)
was added HF-pyridine (70:30, 0.5 ml), and the reaction mixture
was stirred overnight. The reaction mixture was diluted with EtOAc
(120 ml) and washed with a saturated aqueous NaHCO3 solution
(10 ml × 2), a CuSO4 solution (10 ml × 3), water (10 ml × 3), and
brine (3 ml). The organic layer was dried over anhydrous MgSO4,
and solvent was removed under reduced pressure. The residue
was purified by chromatography using 1/1 Hexanes:EtOAc as the
eluent to afford SB-T-2053 as white solid (37 mg, 93%). Mp: 208°C–
210°C. [α]D22 –49 (c 0.92, CHCl3). 1H NMR (500 MHz, CDCl3) δ 1.19
(s, 3 H), 1.23 (s, 3 H), 1.71 (s, 3 H), 1.86 (s, 3 H), 1.91 (m, 1 H), 2.23
(s, 3 H), 2.37 (s, 1 H), 2.55 (s, 3 H), 2.59 (m, 1 H), 2.98 (s, 1 H), 3.23
(d, J = 16.0 Hz, 1 H), 3.35 (s, 1 H), 3.81 (d, J = 6.6 Hz, 1 H), 3.84 (m,
2 H), 3.88 (d, J =8.4 Hz, 1 H), 3.96 (m, 1 H), 4.11 (m, 1 H), 4.25 (d,
J = 9.0 Hz, 1 H), 4.40 (m, 1 H), 4.45 (d, J = 8.4 Hz, 1 H), 4.67 (d, J =
1.8 Hz, 1 H), 5.00 (d, J =1.2 Hz, 1 H), 5.22 (d, J = 5.4 Hz, 1 H), 5.35
(d, J = 16.2 Hz, 1 H), 5.56 (m, 1 H), 6.24 (d, J = 7.8 Hz, 1 H), 6.29
(s, 1 H), 6.71 (d, J = 6.0 Hz, 1 H), 7.17 (d, J = 7.2 Hz, 1 H), 7.28-7.53
(m, 9 H), 7.62 (t, J = 7.2 Hz, 1 H), 8.09 (d, J = 7.2 Hz, 2 H); 13C NMR
(100.5 MHz, CDCl3) δ 9.4, 14.8, 20.8, 23.1, 26.2, 35.7, 37.7, 43.5,
44.9, 55.2, 58.9, 72.0, 72.5, 73.2, 74.6, 75.1, 76.2, 79.3, 79.8,
81.7, 84.3, 125.9, 126.5, 126.9, 127.3, 127.6, 128.2, 128.7, 128.9,
129.3, 129.8, 130.5, 131.4, 133.8, 135.0, 135.5, 137.5, 137.7, 138.1,
165.3, 169.2, 169.6, 171.1, 172.9, 203.0. HRMS calculated for
C51H56NO15H+: 922.3650, found 922.3659.
Supplemental Data
Two supplemental figures are available online at http://www.
chembiol.com/cgi/content/full/12/3/339/DC1/.
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